Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Operating Expenses (2020 - 2023)

Candel Therapeutics' Operating Expenses history spans 4 years, with the latest figure at $10.3 million for Q4 2023.

  • For Q4 2023, Operating Expenses rose 26.88% year-over-year to $10.3 million; the TTM value through Dec 2023 reached $38.4 million, up 10.17%, while the annual FY2024 figure was $33.4 million, 13.08% down from the prior year.
  • Operating Expenses for Q4 2023 was $10.3 million at Candel Therapeutics, up from $8.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $10.3 million in Q4 2023 and bottomed at $2.6 million in Q2 2020.
  • The 4-year median for Operating Expenses is $8.1 million (2022), against an average of $7.4 million.
  • The largest annual shift saw Operating Expenses soared 189.93% in 2021 before it dropped 0.58% in 2023.
  • A 4-year view of Operating Expenses shows it stood at $6.2 million in 2020, then increased by 26.26% to $7.8 million in 2021, then rose by 4.65% to $8.1 million in 2022, then rose by 26.88% to $10.3 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Operating Expenses are $10.3 million (Q4 2023), $8.9 million (Q3 2023), and $9.6 million (Q2 2023).